CD8A and melanoma: We have characterized peripheral iNKT cells in two different tremelimumab clinical trials for patients with advanced melanoma, finding that responders to tremelimumab plus Mart1/DC treatment had higher frequency of the Th1 type CD8+ iNKT cells and a lower frequency Th2/anti-inflammatory CD4+ iNKT cells than non-responders.